ArticleMolecular and cellular biochemistry2026
Eugenol regulates ferroptosis through Mfn2/SLC7A11/GPX4 pathway to alleviate glutamate excitotoxicity damage in glaucoma.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a leading cause of irreversible blindness, characterized by progressive loss of retinal ganglion cells (RGCs), with glutamate excitotoxicity being a key contributor to RGC damage. Eugenol, a natural phenolic compound, has been shown to exhibit neuroprotective properties. However, protective effect of eugenol on glaucoma has not been explored. This study aimed to evaluate neuroprotective effects of eugenol in models of glutamate excitotoxicity and to explore the underlying mechanisms. The glutamate-induced R28 cell excitotoxicity model and N-methyl-D-aspartate (NMDA)-induced mouse glaucoma model were established. Cell Counting Kit-8 (CCK-8), iron ion probes, lipid peroxidation detection and other techniques were employed to elucidate whether eugenol could alleviate glutamate-induced ferroptosis. Subsequently, in vivo validation was performed using C57BL/6J mice. Eugenol significantly attenuated glutamate-induced R28 cell death and RGC damage. Eugenol restored Mitofusin 2 (Mfn2) levels reduced by glutamate excitotoxicity, thereby reducing abnormal lipid droplet (LD) accumulation and alleviating mitochondrial dysfunction. Furthermore, it upregulated solute carrier family 7 member 11 (SLC7A11), increased cellular glutathione (GSH) levels, and activated glutathione peroxidase 4 (GPX4) in an Mfn2-dependent manner, ultimately inhibiting ferroptosis. Eugenol exerts neuroprotective effects in glaucoma excitotoxicity models by suppressing ferroptosis through Mfn2-mediated regulation of mitochondrial-LD homeostasis and the SLC7A11/GSH/GPX4 antioxidant pathway.
Indexed as
Identifiers
42536141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.